Table 1 ATLL patient characteristics,... | American Society of Hematology

Table 1

ATLL patient characteristics, AZT and IFN-α response, c-Rel, and IRF-4 status

Patient	Age, y	ATLL type	WBC count or solid tissue	Surface antigen expression	LDH	↑ Ca²⁺	Antiviral response	c-Rel	IRF-4	Survival, mo
ATLL-1	48	Lymph → acute	13 000	CD4⁺CD25⁺	> 2N	Yes	CR	−	−WB	63+
ATLL-2	37	Acute	37 000	CD4⁺CD25⁺	> 2N	No	CR	−	−WB	63+
ATLL-3	44	Unfavorable chronic	23 000	CD4⁺CD25⁺	< 2N	No	CR	−	−WB	16+
ATLL-4	46	Unfavorable chronic	17 000	CD4⁺CD25⁺CD30⁺	Normal	No	NR	+	+WB	1+
ATLL-5	49	Lymphoma	Bone mass	CD4⁺CD25⁺	Normal	No	NR	+	+WB	17
ATLL-6	36	Acute	126 000	CD4⁺CD25⁺	> 2N	No	NR	+	+WB	1.4
ATLL-7	76	Acute	182 000	CD4⁺CD25⁺	< 2N	Yes	PR	+	+WB	8
ATLL-8	42	Acute	49 000	CD4⁺CD25⁺	> 2N	Yes	PR	−	NA	2
ATLL-9	64	Acute	84 000	CD4⁺CD25⁺	> 2N	Yes	NA	+	NA	1.6
ATLL-10	53	Acute	117 000	CD4⁺CD25⁻	> 2N	Yes	NA	−	−IHC LN	3
ATLL-11	50	Lymph → acute	53 000	CD4⁺CD25⁺	> 2N	Yes	NR	−	+IHC skin	5.5
ATLL-12	66	Acute	42 000	CD4⁺CD25⁻	> 2N	Yes	NA	−	NA	4
ATLL-13	68	Acute	108 000	CD4⁺	> 2N	Yes	NA	+	NA	0.3
ATLL-14	70	Acute	144 000	CD4⁺CD25⁺	> 2N	No	PR	−	−WB	2.5+
ATLL-15	37	Acute	70 000	CD4⁺CD25⁺	> 2N	No	NR	−	−WB	8
ATLL-16	52	Acute	127 000	CD4⁺CD25⁺	> 2N	Yes	NA	−	NA	2
ATLL-17	27	Acute	139 000	CD4⁺CD25⁻	> 2N	No	NR	−	−WB	5
ATLL-18	44	Acute	63 000	CD4⁺	> 2N	Yes	NA	−	NA	0.7
ATLL-19	74	Chronic	21 000	CD4⁺CD25⁺	NA	No	Untreated	−	NA	3+
ATLL-20	66	Lymph → acute	34 000	CD4⁺CD25⁻	> 2N	Yes	NR	+ LN	+WB, IHC LN	3.5
ATLL-21	29	Unfavorable chronic	61 000	CD4⁺CD25⁺CD30⁻	< 2N	No	CR	−	−WB	4+
ATLL-22	69	Acute	144 000	CD4⁺CD25⁺	> 2N	Yes	NR	+	+WB	5
ATLL-23	69	Lymphoma	Colon mass	CD3⁺CD30⁺ (IHC)	Normal	No	*	−	+IHC	6.5
ATLL-24	67	Acute	81 000	CD4⁺CD25⁻	> 2N	Yes	PR	−	−WB	4+
ATLL-25	52	Acute	102 000	CD4⁺CD25⁺	> 2N	Yes	NR	+	NA	2.5
ATLL-26	50	Acute	63 000	CD4⁺CD25⁺	< 2N	No	NR	−	+WB	21+
ATLL-27	46	Acute	89 000	CD4⁺CD25⁺	> 2N	Yes	CR	−	−WB	7+
ATLL-28	41	Lymphoma	Bone marrow	CD4⁺CD25⁺	< 2N	Yes	NR	NA	+ IHC	5
ATLL-29	57	Lymphoma	Lymph node	CD3⁺CD30⁻ (IHC)	< 2N	No	*	NA	+ IHC	21+
ATLL-30	50	Lymphoma	Lymph node	CD4⁺CD25⁺	> 2N	Yes	NR	NA	+ IHC	7+
ATLL-31	34	Lymphoma	Chest mass	CD3⁺CD30⁺ (IHC)	> 2N	No	NA	NA	+ IHC	39
ATLL-32	43	Lymphoma	Lymph node	CD4⁺CD25⁺	> 2N	No	*	NA	+IHC	5
ATLL-33	36	Lymphoma	Lymph node	CD3⁺ (IHC)	> 2N	No	*	NA	+ IHC	17
ATLL-34	45	Lymphoma	Lymph node	CD4+CD25−	< 2N	No	NR	NA	+ IHC	6.5
ATLL-35	34	Lymphoma	Lymph node	CD4⁺CD25⁺CD30⁻	> 2N	Yes	NA	NA	+ IHC	4+
ATLL-36	66	Lymphoma	Oral mass	CD4⁺CD25⁺	Normal	No	*	NA	+ IHC	30
ATLL-37	36	Lymphoma	Lymph node	CD4⁺CD25⁺CD30⁺	> 2N	No	NA	NA	+ IHC	10
ATLL-38	56	Lymphoma	Lymph node	CD4⁺CD25⁺	> 2N	No	NA	NA	+IHC	9

Patient	Age, y	ATLL type	WBC count or solid tissue	Surface antigen expression	LDH	↑ Ca²⁺	Antiviral response	c-Rel	IRF-4	Survival, mo
ATLL-1	48	Lymph → acute	13 000	CD4⁺CD25⁺	> 2N	Yes	CR	−	−WB	63+
ATLL-2	37	Acute	37 000	CD4⁺CD25⁺	> 2N	No	CR	−	−WB	63+
ATLL-3	44	Unfavorable chronic	23 000	CD4⁺CD25⁺	< 2N	No	CR	−	−WB	16+
ATLL-4	46	Unfavorable chronic	17 000	CD4⁺CD25⁺CD30⁺	Normal	No	NR	+	+WB	1+
ATLL-5	49	Lymphoma	Bone mass	CD4⁺CD25⁺	Normal	No	NR	+	+WB	17
ATLL-6	36	Acute	126 000	CD4⁺CD25⁺	> 2N	No	NR	+	+WB	1.4
ATLL-7	76	Acute	182 000	CD4⁺CD25⁺	< 2N	Yes	PR	+	+WB	8
ATLL-8	42	Acute	49 000	CD4⁺CD25⁺	> 2N	Yes	PR	−	NA	2
ATLL-9	64	Acute	84 000	CD4⁺CD25⁺	> 2N	Yes	NA	+	NA	1.6
ATLL-10	53	Acute	117 000	CD4⁺CD25⁻	> 2N	Yes	NA	−	−IHC LN	3
ATLL-11	50	Lymph → acute	53 000	CD4⁺CD25⁺	> 2N	Yes	NR	−	+IHC skin	5.5
ATLL-12	66	Acute	42 000	CD4⁺CD25⁻	> 2N	Yes	NA	−	NA	4
ATLL-13	68	Acute	108 000	CD4⁺	> 2N	Yes	NA	+	NA	0.3
ATLL-14	70	Acute	144 000	CD4⁺CD25⁺	> 2N	No	PR	−	−WB	2.5+
ATLL-15	37	Acute	70 000	CD4⁺CD25⁺	> 2N	No	NR	−	−WB	8
ATLL-16	52	Acute	127 000	CD4⁺CD25⁺	> 2N	Yes	NA	−	NA	2
ATLL-17	27	Acute	139 000	CD4⁺CD25⁻	> 2N	No	NR	−	−WB	5
ATLL-18	44	Acute	63 000	CD4⁺	> 2N	Yes	NA	−	NA	0.7
ATLL-19	74	Chronic	21 000	CD4⁺CD25⁺	NA	No	Untreated	−	NA	3+
ATLL-20	66	Lymph → acute	34 000	CD4⁺CD25⁻	> 2N	Yes	NR	+ LN	+WB, IHC LN	3.5
ATLL-21	29	Unfavorable chronic	61 000	CD4⁺CD25⁺CD30⁻	< 2N	No	CR	−	−WB	4+
ATLL-22	69	Acute	144 000	CD4⁺CD25⁺	> 2N	Yes	NR	+	+WB	5
ATLL-23	69	Lymphoma	Colon mass	CD3⁺CD30⁺ (IHC)	Normal	No	*	−	+IHC	6.5
ATLL-24	67	Acute	81 000	CD4⁺CD25⁻	> 2N	Yes	PR	−	−WB	4+
ATLL-25	52	Acute	102 000	CD4⁺CD25⁺	> 2N	Yes	NR	+	NA	2.5
ATLL-26	50	Acute	63 000	CD4⁺CD25⁺	< 2N	No	NR	−	+WB	21+
ATLL-27	46	Acute	89 000	CD4⁺CD25⁺	> 2N	Yes	CR	−	−WB	7+
ATLL-28	41	Lymphoma	Bone marrow	CD4⁺CD25⁺	< 2N	Yes	NR	NA	+ IHC	5
ATLL-29	57	Lymphoma	Lymph node	CD3⁺CD30⁻ (IHC)	< 2N	No	*	NA	+ IHC	21+
ATLL-30	50	Lymphoma	Lymph node	CD4⁺CD25⁺	> 2N	Yes	NR	NA	+ IHC	7+
ATLL-31	34	Lymphoma	Chest mass	CD3⁺CD30⁺ (IHC)	> 2N	No	NA	NA	+ IHC	39
ATLL-32	43	Lymphoma	Lymph node	CD4⁺CD25⁺	> 2N	No	*	NA	+IHC	5
ATLL-33	36	Lymphoma	Lymph node	CD3⁺ (IHC)	> 2N	No	*	NA	+ IHC	17
ATLL-34	45	Lymphoma	Lymph node	CD4+CD25−	< 2N	No	NR	NA	+ IHC	6.5
ATLL-35	34	Lymphoma	Lymph node	CD4⁺CD25⁺CD30⁻	> 2N	Yes	NA	NA	+ IHC	4+
ATLL-36	66	Lymphoma	Oral mass	CD4⁺CD25⁺	Normal	No	*	NA	+ IHC	30
ATLL-37	36	Lymphoma	Lymph node	CD4⁺CD25⁺CD30⁺	> 2N	No	NA	NA	+ IHC	10
ATLL-38	56	Lymphoma	Lymph node	CD4⁺CD25⁺	> 2N	No	NA	NA	+IHC	9

ATLL type classified as acute, lymphoma, chronic, or unfavorable chronic according to Japanese Lymphoma Study Group definitions.² Lymph → acute indicates previously diagnosed with lymphoma type and progressed to leukemia before AZT and IFN-α as induction therapy; age, patient age at time of diagnosis; WBC, white blood cell count in cells/mm³ immediately before antiviral therapy and blood collection for molecular studies; solid tissue, when specified, biopsy specimens were used for immunophenotypic and molecular studies; surface Ag expression, cell surface antigen (CD3, CD4, CD25, CD30) expression status (indicated by predominantly + or −) by flow cytometry or immunostains (IHC) (these data were available at Jackson Memorial Hospital; if not reported, data were unavailable); lactose dehydrogenase (LDH), > 2N, more than twice the normal value (per Shimoyama²); < 2N, elevated but less than twice the normal value; NA, data not available or not evaluable; ↑Ca²⁺, hypercalcemia; antiviral response, response to induction with high-dose parenteral AZT and IFN-α; *, patients who received oral AZT and subcutaneous IFN-α as outpatient (not as induction) therapy after previous therapies; c-Rel, nuclear expression by EMSA; +, overexpression; −, comparable to negative controls; IRF-4, protein expression measured by Western blot (WB), immunohistochemistry (IHC), or both; +, expression; −, no expression; NA, data not available; LN, lymph node, and skin biopsy tissues were available for IHC for the specified patients; survival, in months from the time of diagnosis, regardless of therapies received; +, censored survival times.

View Large

This Feature Is Available To Subscribers Only